NVAX stock rises as Novavax updates its 2026 outlook

Novavax (US66987V1098) stock is trading against a 2026 backdrop shaped by fiscal 2025 guidance of $650 million to $700 million in revenue, after the company reported $682 million in product revenue for 2024 and $8.7 million in net income for 2024. The latest filing and company reporting also showed $692 million in cash and cash equivalents at 31 December 2024, a figure that helps frame how much room Novavax has to execute.

Revenue guide near 2024 sales

The revenue range for fiscal 2025 sits close to the $682 million product revenue base reported for 2024, which makes the guidance a continuation story rather than a sharp step change. That comparison matters because the company still has to convert its 2024 sales base into durable operating results, and the reported $8.7 million net income in 2024 was thin relative to the scale of revenue.

Cash also matters. Novavax ended 2024 with $692 million in cash and cash equivalents, and that balance gives investors a concrete measure to track against future spending, licensing income, and commercial execution.

Cash and earnings matter

For a company like Novavax, the balance between revenue, profitability, and liquidity is the core market issue. A 2024 product revenue figure of $682 million, net income of $8.7 million, and cash of $692 million all point to a business that is still highly sensitive to the next year of demand and expense control.

The market angle is simple: the numbers are large enough to matter, but the margin remains narrow. That makes any update on revenue mix, cost discipline, or commercialization more important than a broad company profile.

Product focus stays central

Novavax remains a vaccine company at heart, and its commercial performance still depends on product uptake and licensing-related execution. The body of evidence available in the company figures points to a business where 2024 revenue, 2024 earnings, and year-end cash are more informative than broad narrative optimism.

That is why the fiscal 2025 revenue guide matters so much. If management can hold revenue near the 2024 level while protecting cash and improving earnings quality, the stock will likely continue to trade on the credibility of those numbers rather than on a story alone.

2024 sales set the frame

Novavax reported $682 million in product revenue for 2024, $8.7 million in net income for 2024, and $692 million in cash and cash equivalents at 31 December 2024. Those three figures define the current financial frame: a sizable sales base, limited profit, and a cash cushion that investors will keep watching through 2025.

The fiscal 2025 revenue guide of $650 million to $700 million suggests management expects a broadly stable top line relative to 2024, not a dramatic jump. For Novavax stock, that makes the quality of earnings and cash conversion the key numbers, not just the revenue headline.

Novavax vaccine business

The companys vaccine business remains the central product story behind the financials. The commercial relevance comes from how that business translates into product revenue, and the 2024 figure of $682 million shows the scale still in play.

Net income was only $8.7 million in 2024, so even modest changes in pricing, demand, or expense structure can have an outsized effect on the bottom line. Investors reading the latest Novavax stock setup therefore need to compare revenue guidance with the cash balance and profit base, not with revenue alone.

Cash at year end

At 31 December 2024, Novavax had $692 million in cash and cash equivalents. That year-end balance is the clearest dated market value available in the source set and remains a practical reference point for judging the companys operating runway.

Novavax stock closed the latest available comparison window with its 2024 fundamentals still setting the tone: $682 million in product revenue, $8.7 million in net income, and $692 million in cash and cash equivalents. The fiscal 2025 revenue guide of $650 million to $700 million keeps the company tied to those same core numbers.